1
|
Moore PF. Histiocytic Diseases. Vet Clin North Am Small Anim Pract 2023; 53:121-140. [DOI: 10.1016/j.cvsm.2022.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
McPhetridge JB, Scharf VF, Regier PJ, Toth D, Lorange M, Tremolada G, Dornbusch JA, Selmic LE, Bae S, Townsend KL, McAdoo JC, Thieman KM, Solari F, Walton RA, Romeiser J, Tuohy JL, Oblak ML. Distribution of histopathologic types of primary pulmonary neoplasia in dogs and outcome of affected dogs: 340 cases (2010-2019). J Am Vet Med Assoc 2022; 260:234-243. [PMID: 34851850 DOI: 10.2460/javma.20.12.0698] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To provide updated information on the distribution of histopathologic types of primary pulmonary neoplasia in dogs and evaluate the effect of postoperative adjuvant chemotherapy in dogs with pulmonary carcinoma. ANIMALS 340 dogs. PROCEDURES Medical records of dogs that underwent lung lobectomy for removal of a primary pulmonary mass were reviewed, and histopathologic type of lesions was determined. The canine lung carcinoma stage classification system was used to determine clinical stage for dogs with pulmonary carcinoma. RESULTS Pulmonary carcinoma was the most frequently encountered tumor type (296/340 [87.1%]), followed by sarcoma (26 [7.6%]), adenoma (11 [3.2%]), and pulmonary neuroendocrine tumor (5 [1.5%]); there was also 1 plasmacytoma and 1 carcinosarcoma. Twenty (5.9%) sarcomas were classified as primary pulmonary histiocytic sarcoma. There was a significant difference in median survival time between dogs with pulmonary carcinomas (399 days), dogs with histiocytic sarcomas (300 days), and dogs with neuroendocrine tumors (498 days). When dogs with pulmonary carcinomas were grouped on the basis of clinical stage, there were no significant differences in median survival time between dogs that did and did not receive adjuvant chemotherapy. CLINICAL RELEVANCE Results indicated that pulmonary carcinoma is the most common cause of primary pulmonary neoplasia in dogs; however, nonepithelial tumors can occur. Survival times were significantly different between dogs with pulmonary carcinoma, histiocytic sarcoma, and neuroendocrine tumor, emphasizing the importance of recognizing the relative incidence of these various histologic diagnoses. The therapeutic effect of adjuvant chemotherapy in dogs with pulmonary carcinoma remains unclear and warrants further investigation.
Collapse
Affiliation(s)
- Jourdan B McPhetridge
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - Valery F Scharf
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - Penny J Regier
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL
| | - Darby Toth
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL
| | - Max Lorange
- Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
| | - Giovanni Tremolada
- Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
| | - Josephine A Dornbusch
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University Columbus, OH
| | - Laura E Selmic
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University Columbus, OH
| | - Sohee Bae
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR
| | - Katy L Townsend
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR
| | - Jack C McAdoo
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
| | - Kelley M Thieman
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
| | - Francesca Solari
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA
| | - Rebecca A Walton
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA
| | - Jacob Romeiser
- Department of Small Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA
| | - Joanne L Tuohy
- Department of Small Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA
| | - Michelle L Oblak
- Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| |
Collapse
|
3
|
Murray CA, Willcox JL, De Mello Souza CH, Husbands B, Cook MR, Clifford C, Leeper H, Pellin M, Richardson D, Herrera CL, Krick E, McMillan S, Al-Nadaf S, Skorupski KA. Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma. Vet Comp Oncol 2021; 20:458-464. [PMID: 34878710 DOI: 10.1111/vco.12791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 11/24/2021] [Accepted: 11/26/2021] [Indexed: 11/28/2022]
Abstract
Primary pulmonary histiocytic sarcoma (PHS) is a rare form of dendritic cell or macrophage neoplasia originating within the pulmonary parenchyma. There is limited literature describing prognosis in dogs with PHS receiving curative-intent treatment consisting of surgical excision and adjuvant chemotherapy. The primary objective of this study was to report outcomes in dogs with localized PHS treated with standardized local and systemic therapy. A secondary objective was to identify prognostic factors in this population. A multi-institutional retrospective study was performed and medical records including all surgical and histopathologic reports were retrospectively reviewed. For inclusion, dogs were required to have confirmed localized PHS and they must have undergone curative-intent surgery with resection of all gross primary tumour and enlarged tracheobronchial lymph nodes; additionally, they must have received curative-intent treatment with adjuvant single-agent CCNU chemotherapy. Twenty-seven dogs from six veterinary teaching hospitals and five private practices treated from 2008-2019 were included. The overall median survival time was 432 days. Higher CCNU dose was demonstrated to have a negative impact on survival on univariate, but not multivariable, analysis. Factors that were not found to be associated with survival on univariate analysis included body weight, breed, clinical signs at the time of diagnosis, hypoalbuminaemia, tumour size, lung lobe affected, lymph node metastasis, surgical margins and CCNU dose reductions. This study supports a favourable prognosis for dogs diagnosed with localized PHS treated with curative-intent surgery in addition to adjuvant CCNU chemotherapy and suggests that multimodal treatment may be advisable to attempt to prolong survival.
Collapse
Affiliation(s)
- Caroline A Murray
- William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, California, USA
| | - Jennifer L Willcox
- Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA
| | - Carlos H De Mello Souza
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
| | - Brian Husbands
- Department of Veterinary and Clinical Sciences, Ohio State University, Columbus, Ohio, USA
| | - Matthew R Cook
- Department of Veterinary and Clinical Sciences, Ohio State University, Columbus, Ohio, USA
| | - Craig Clifford
- Hope Veterinary Specialists/BluePearl Malvern, Malvern, Pennsylvania, USA
| | - Haley Leeper
- Department of Clinical Sciences, Oregon State University, Corvallis, Oregon, USA
| | - MacKenzie Pellin
- Department of Medical Sciences, University of Wisconsin, Madison, Wisconsin, USA
| | - Danielle Richardson
- Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario, USA
| | - Chamisa L Herrera
- Boundary Bay Veterinary Specialty Hospital, Langley, British Columbia, Canada
| | - Erika Krick
- Mount Laurel Animal Hospital, Mount Laurel, New Jersey, USA
| | - Sarah McMillan
- Veterinary Emergency + Referral Center of Hawaii, Honolulu, Hawaii, USA
| | - Sami Al-Nadaf
- Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA
| | - Katherine A Skorupski
- Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA
| |
Collapse
|
4
|
Mumaw JL, Clarke L, Butt SL, Uhl E. Pathology in Practice. J Am Vet Med Assoc 2020; 254:1057-1059. [PMID: 30986151 DOI: 10.2460/javma.254.9.1057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
5
|
Purzycka K, Peters LM, Elliott J, Lamb CR, Priestnall SL, Hardas A, Johnston CA, Rodriguez-Piza I. Histiocytic sarcoma in miniature schnauzers: 30 cases. J Small Anim Pract 2020; 61:338-345. [PMID: 32323304 DOI: 10.1111/jsap.13139] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 03/13/2020] [Accepted: 03/14/2020] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma. MATERIALS AND METHODS Retrospective review of medical records of miniature schnauzers diagnosed with histiocytic sarcoma between 2008 and 2019 at two referral centres in the UK. Signalment, clinical signs at initial presentation, imaging results and clinico- and histopathological findings, treatment type and outcome were recorded. Progression-free survival and overall survival time were calculated. RESULTS Thirty dogs were included. Twenty-four of 29 dogs undergoing imaging of the thorax had lung and/or mediastinal involvement. The median overall survival time for dogs that were not euthanased within 3 days of diagnosis was 117 days (range 10 to 790). Three dogs underwent surgery; 13 received treatment with lomustine as a sole therapy - with partial responses documented on imaging in five of six dogs and 11 of 13 showing clinical improvement. CLINICAL SIGNIFICANCE Histiocytic sarcoma should be considered as a differential diagnosis for miniature schnauzers with pulmonary masses. Although responses to treatment were common, they were usually short-lived because of the aggressive nature of the disease.
Collapse
Affiliation(s)
- K Purzycka
- Queen Mother Hospital for Animals, Royal Veterinary College, University of London, North Mymms, UK
| | - L M Peters
- Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hatfield, UK
| | - J Elliott
- North Carolina State University, Department of Radiation Oncology, 1060 William Moore Drive, Raleigh, NC, 27606, USA
| | - C R Lamb
- Queen Mother Hospital for Animals, Royal Veterinary College, University of London, North Mymms, UK
| | - S L Priestnall
- Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hatfield, UK
| | - A Hardas
- Anderson Moores Veterinary Specialists, The Granary, Bunstead Barns, Winchester, UK
| | - C A Johnston
- Queen Mother Hospital for Animals, Royal Veterinary College, University of London, North Mymms, UK
| | - I Rodriguez-Piza
- Department of Oncology, Hospital Veterinari Glòries, Barcelona, Spain
| |
Collapse
|
6
|
Marlowe KW, Robat CS, Clarke DM, Taylor A, Touret M, Husbands BD, Vail DM. Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015). Vet Comp Oncol 2018; 16:658-663. [PMID: 30246460 DOI: 10.1111/vco.12437] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 03/12/2018] [Accepted: 03/14/2018] [Indexed: 11/30/2022]
Abstract
Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.
Collapse
Affiliation(s)
- Katelyn W Marlowe
- Department of Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin
| | - Cecilia S Robat
- Veterinary Emergency Service/Veterinary Specialty Center, Middleton, Wisconsin
| | - Dawn M Clarke
- Department of Small Animal Medicine and Surgery, Veterinary Clinical Sciences Department, University of Georgia, Athens, Georgia
| | - Angela Taylor
- Department of Clinical Science and Services, Royal Veterinary College, London, UK
| | - Maude Touret
- Medical Oncology Department, Centre Vétérinaire Laval, Laval, Quebec, Canada
| | - Brian D Husbands
- Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul, Minnesota
| | - David M Vail
- Department of Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin.,Carbone Cancer Center, Madison, Wisconsin
| |
Collapse
|
7
|
Lenz JA, Furrow E, Craig LE, Cannon CM. Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition? J Small Anim Pract 2017; 58:461-467. [PMID: 28543363 DOI: 10.1111/jsap.12688] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 01/17/2017] [Accepted: 01/27/2017] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To describe a series of miniature schnauzers diagnosed with histiocytic sarcoma and assess for possible breed predisposition. MATERIALS AND METHODS Medical records of miniature schnauzers with a diagnosis of histiocytic sarcoma between January 2008 and April 2015 were reviewed. Data collected included signalment, body weight, presenting complaint, date of diagnosis, clinicopathologic and diagnostic imaging findings, treatment, therapeutic response, date of death or last follow-up and necropsy findings. Breed predisposition was assessed with odds ratios, using breed-matched dogs without histiocytic sarcoma admitted during the study period as controls. Pedigree analysis was performed for dogs with available registration information. RESULTS Fourteen miniature schnauzers were diagnosed with histiocytic sarcoma during the study period, making them over-represented among the hospital population (odds ratio=4·8, P=0·0009). Disease was considered localised in ten dogs and disseminated in four. Of the dogs with localised disease, nine were diagnosed with primary pulmonary histiocytic sarcoma based on the presence of a large pulmonary mass with (n=7) or without (n=2) evidence of intra-thoracic metastasis, and one had gastric histiocytic sarcoma with nodal metastasis. Treatments varied, but an aggressive clinical course was found in most patients. Pedigree analysis revealed a recent common ancestor for a subset of the dogs assessed. CLINICAL SIGNIFICANCE Miniature schnauzers were over-represented among dogs with histiocytic sarcoma in this patient population. Pedigree analysis supports an inherited risk factor, which has not previously been suggested in the breed. Primary pulmonary involvement with or without intra-thoracic metastasis was common in this cohort.
Collapse
Affiliation(s)
- J A Lenz
- Department of Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, 37996, USA
| | - E Furrow
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, 55455, USA
| | - L E Craig
- Department of Pathobiology, University of Tennessee, Knoxville, Tennessee, 37996, USA
| | - C M Cannon
- Department of Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, 37996, USA
| |
Collapse
|